Streetbeat News

Products Services

SLN

Silence Therapeutics has reported topline results from its Phase 1 multiple dose study of Zerlasiran. The study found that Lp(a) levels remained around 90% lower than baseline at the study endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:12 am

MNPR

Monopar Therapeutics has presented data at the 2023 Connective Tissue Oncology Society Annual Meeting showing that Camsirubicin, in an ongoing Phase 1b trial, has demonstrated tumor reduction benefits in patients with advanced soft tissue sarcoma.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:06 am

FYBR

Frontier Communications has expanded its fiber network to an additional 332,000 locations in Q3. This is part of the company's ongoing efforts to increase its fiber footprint.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 11:01 am

GTBIF

Green Thumb Industries (GTBIF) has partnered with Magnolia Bakery to launch two limited-edition THC-infused chocolate bars. The products will be available at RISE Dispensaries in Illinois, Nevada, and Massachusetts from November 1st, with wider availability in these states starting the following week. This is Magnolia Bakery's first venture into the cannabis industry.

Portfolio Pulse from Nina Zdinjak

November 01, 2023 | 11:00 am

ACM

AECOM (ACM) has been chosen to provide engineering services for Metro Vancouver's Stoney Creek Trunk Sewer upgrade. The financial terms of the deal have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:56 am

MRK

The FDA has approved Merck's KEYTRUDA in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. This approval could potentially increase Merck's market share in the cancer treatment sector.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:52 am

IRIX

Iridex has announced that the Local Coverage Determination L39620 Micro-Invasive Glaucoma Surgery will likely limit the patient types for which WPS Government Health Administrator will reimburse Cyclophotocoagulation procedures after December 24, 2023. This decision by WPS, a Medicare Administrative Contractor, could impact the use of Iridex's Cyclo G6 Laser System and Probe Delivery Devices in ophthalmology.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:49 am

MRK

Merck's Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, an anti-PD-1 therapy, has met its key secondary endpoint of overall survival. Previously, the trial had met its primary endpoint of disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 10:37 am

F

GM

STLA

Stellantis NV's Chrysler has recalled over 97,000 Jeep Grand Wagoneer and Wagoneer SUV vehicles due to faulty seat belts. The company will replace the seat belt buckle free of charge. This year, Chrysler has issued 40 recalls affecting over 2.5 million vehicles, second only to Ford Motor Co. which has issued 48 recalls affecting 5.4 million vehicles. General Motors Co. has issued 19 recalls.

Portfolio Pulse from Anan Ashraf

November 01, 2023 | 10:05 am

TSLA

Tesla CEO Elon Musk recently stated that the company aims to produce 200,000 units of Cybertruck per year, which is a downward adjustment from the previous guidance of 250,000 units per year. This has led to questions about whether this is an official guidance cut or a slip. Despite the production challenges, demand for the Cybertruck remains strong with over 2 million reservations. Tesla's stock ended Tuesday's session up 1.76% to $200.84.

Portfolio Pulse from Shanthi Rexaline

November 01, 2023 | 9:58 am